Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 18/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.42 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2811428 | 0.99 | IL2 (0.65) | IL2NPC1RAB9ALMNATNF | |
| SCHEMBL8236221 | 0.96 | IL2 (0.61) | IL2NPC1RAB9ASTIM1ORAI1 | |
| SCHEMBL4762567 | 0.89 | IL2 (0.71) | IL2TNFSTIM1ORAI1 | |
| SCHEMBL2812935 | 0.89 | IL2 (0.54) | IL2NPC1RAB9ALMNA | |
| Hydrochloric Acid SCHEMBL2813897 | 0.88 | IL2 (0.53) | IL2NPC1RAB9ALMNA | |
| SCHEMBL5554286 | 0.87 | IL2 (0.69) | IL2STIM1ORAI1 | |
| SCHEMBL2814805 | 0.86 | IL2 (0.53) | IL2NPC1RAB9A | |
| SCHEMBL8261671 | 0.85 | IL2 (0.66) | IL2TNFSTIM1ORAI1 | |
| SCHEMBL2811967 | 0.84 | IL2 (0.52) | IL2NPC1RAB9ALMNA | |
| SCHEMBL2813970 | 0.84 | CYP11B2 (0.47) | IL2NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140187586-A1 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-07-03 | — | — | US | claimed |
| US-8710083-B2 | Pyridylphenyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-04-29 | — | — | US | claimed |
| EP-1984338-B1 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2013-01-16 | — | — | EP | claimed |
| US-20100249195-A1 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2010-09-30 | — | — | US | claimed |
| EP-1984338-A2 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-10-29 | — | — | EP | claimed |
| US-20070254926-A1 | Pyridylphenyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-11-01 | — | — | US | claimed |
| WO-2007089904-A2 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-09 | — | — | WO | claimed |
| US-20140187586-A1 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187586-A1 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187586-A1 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-07-03 | — | — | US | disclosed |
| US-8710083-B2 | Pyridylphenyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710083-B2 | Pyridylphenyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710083-B2 | Pyridylphenyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20100249195-A1 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249195-A1 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249195-A1 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2010-09-30 | — | — | US | disclosed |
| EP-1984338-A2 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070254926-A1 | Pyridylphenyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-11-01 | — | — | US | disclosed |
| US-20070254926-A1 | Pyridylphenyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-11-01 | — | — | US | disclosed |
| WO-2007089904-A2 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254926-A1 | Pyridylphenyl compounds for inflammation and immune-related uses | CCR1, CXCR3, NLRP1 | IL2 77/4885NPC1 947/4885RAB9A 2696/4885 |
| US-20140187586-A1 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CXCR3, NLRP1 | IL2 77/4885NPC1 947/4885RAB9A 2696/4885 |
| US-20100249195-A1 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CXCR3, NLRP1 | IL2 77/4885NPC1 947/4885RAB9A 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.